In the News

The US Food and Drug Administration (FDA) approved burosumab-twza (Crysvita) injection to treat patients aged 2 years and older with tumour-induced osteomalacia (TIO). “Treatment for TIO focuses on identifying and removing the tumour that causes the disease; however, when that is not possible, [...
The US Food and Drug Administration (FDA) has approved canakinumab (Ilaris) injection for the treatment of active Still’s Disease, including adult-onset Still’s Disease (AOSD). “Prior to today’s approval, patients had no FDA-approved treatments for their disease, which can include symptoms such as...
The American College of Rheumatology (ACR) has published new guidelines for the management of gout. The updated guideline, published in Arthritis Care...
Autoimmunity appears to be increasing in the United States, according to a study published in Arthritis and Rheumatology. Frederick Miller, MD, National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health, Bethesda, Maryland, and colleagues found that the...
Use of low-dose methotrexate is associated with small to moderate elevations in risks for skin cancer and gastrointestinal, infectious, pulmonary, and haematologic adverse events, according to a study published in the Annals of Internal Medicine. Methotrexate is the most commonly used drug for...

Conference Reports

By Eric Ramos

CHICAGO -- June 12, 2020 -- An intra-articular injection of JTA-004, a novel enhanced protein solution that is supplemented with hyaluronic acid and clonidine, improved pain in patients with knee osteoarthritis, according to a study presented at the 2020 Virtual Meeting of...

By Eric Ramos

CHICAGO -- June 11, 2020 -- A set of antibody biomarkers can help predict which patients with rheumatoid arthritis (RA) will respond to therapy, according to a study presented at the 2020 Virtual Meeting of the European League Against Rheumatism (EULAR).

“For...

By Eric Ramos

CHICAGO -- June 9, 2020 -- Long-term treatment with canakinumab was safe and effective for patients with colchicine-resistant familial Mediterranean fever, according to a study presented at the 2020 Virtual Meeting of the European League Against Rheumatism (EULAR).

“...

By Eric Ramos

CHICAGO -- June 9, 2020 -- Therapeutic drug monitoring in patients with rheumatic diseases who are starting treatment with infliximab does not appear to be superior to standard treatment in order to achieve remission, according to a study presented at the 2020 Virtual...

By Eric Ramos

CHICAGO -- June 8, 2020 -- Colchicine 1 mg/day for 12 weeks was not effective in improving pain, tender and swollen joint count, or grip strength in patients with symptomatic hand osteoarthritis, according to a study presented at the 2020 Virtual Meeting of the European...

Recently Published

Cardiology in the Young
Sevcan Erdem, Fadli Demir, Mustafa Ayana, Oguz Canan, Yankı Kaan Okuducu, Alev Arslan, Osman Kucukosmanoglu, Nazan Özbarlas
BMJ Case Reports
Andrew Bergeron, Thomas Lewellen, Bhavesh Joshi
Deutsche Medizinische Wochenschrift
Hannes Roicke, Wolfgang Köhler, Petra Baum, Christoph Baerwald, Marco Krasselt
Deutsche Medizinische Wochenschrift
Stylianos Tomaras, Jörn Kekow, Eugen Feist

Full-Text Articles

BMC Musculoskeletal Disorders
Zhuoran Hu, Shuiming Xu, He Lin, Weifeng Ni, Qingyuan Yang, Jun Qi, Keqian Du, Jieruo Gu, Zhiming Lin
BMC Musculoskeletal Disorders
Ylva Borgas, Anders Gülfe, Mikael Kindt, Anna Stefánsdóttir
Annals of the Rheumatic Diseases (ARD Online)
Seza Ozen, Eldad Ben-Cherit, Ivan Foeldvari, Gil Amarilyo, Huri Ozdogan, Steven Vanderschueren, Katherine Marzan, J Michelle Kahlenberg, Elise Dekker, Fabrizio De Benedetti, Isabelle Koné-Paut
Reumatología Clinica
Iván Posso-Osorio, Ivana Nieto-Aristizábal, Danny Soto, Camila Ariza, Mónica Urbano, Carlos A Cañas, Alex Echeverri, Alejandro Castillo, Gabriel J Tobón